文献速递造血干细胞移植与细胞治疗血栓与止血

异基因反应介导的造血干细胞移植后内皮细胞并发症:呼吁共识性定义

Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.
PubMed 文献 · Blood Adv · 2019-01-01

该综述聚焦异基因造血干细胞移植后由内皮细胞激活触发的一组罕见且凶险的并发症,包括毛细血管渗漏综合征、植入综合征、移植相关微血管病、弥漫性肺泡出血和特发性肺炎综合征。文章回顾了这些综合征的发生率、临床特征和治疗策略,指出缺乏统一定义阻碍了文献比较,呼吁制定国际公认的标准定义。

要点

  • 移植后内皮细胞激活综合征包括毛细血管渗漏、植入综合征、移植相关微血管病、肺泡出血和特发性肺炎综合征。
  • 异基因反应被认为是共同触发因素,但化疗、感染和钙调神经磷酸酶抑制剂也可诱发。
  • 缺乏统一定义导致文献无法清晰比较,治疗缓解率和生存率仍不理想。

核心结论

  • 异基因反应介导的内皮细胞激活可触发移植后多种罕见且凶险的并发症,亟需国际共识定义以规范诊断和比较研究。

研究设计与样本

  • 综述性文章,回顾了移植后内皮细胞激活综合征的发生率、临床特征和治疗策略。

主要发现

  • 内皮损伤可激活促凋亡、促凝血和促炎症等有害通路,并可能导致多器官衰竭。
  • 各综合征临床表现相互重叠,且与移植物抗宿主病的关系可能很小。
  • 现有治疗手段针对内皮功能障碍的致病机制,但缓解率和生存率仍大多不令人满意。

临床怎么用

  • 临床应识别移植后内皮细胞激活相关综合征的重叠表现,并关注异基因反应这一共同触发因素。
  • 目前尚无公认诊断标准,治疗决策需个体化,期待国际共识定义指导未来实践。

局限性

  • 缺乏明确定义的诊断标准,导致当前文献无法进行清晰比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endothelial cell (EC) activation has been suspected of triggering a group of rare and dismal complications that can occur after allogeneic hematopoietic stem cell transplantation (HSCT). Capillary leak syndrome, engraftment syndrome, transplant-associated microangiopathy, diffuse alveolar hemorrhage, and idiopathic pneumonia syndrome are the main nosological entities. Post-HSCT endotheliitis can be triggered by chemotherapy, infections, and calcineurin inhibitors, but allogeneic reactivity is claimed to be the common denominator. Endothelial damages are thought to activate several deleterious pathways (proapoptotic, procoagulant, proinflammatory) and can lead to multiorgan failure; however, clinical manifestations of each syndrome overlap, and their relationship with graft-versus-host disease could be minimal. The lack of well-defined diagnostic criteria does not allow for a clear-cut comparison in the current literature. Therapeutic efforts have been made to intercept the pathogenic mechanisms leading to EC dysfunction, but remission rates and survival remain mostly unsatisfactory. In this article, we have reviewed the incidence, clinical features, and treatment approaches of EC activation syndromes, and we plead for the development of internationally accepted standard definitions.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pagliuca S, Michonneau D, Sicre de Fontbrune F, et al. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019. PMID: 31409584. doi:10.1182/bloodadvances.2019000143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。